Why shareholders are suing Novo Nordisk over next-generation weight-loss drug
Source:
cnbc
July 29, 2026 · 06:11
Investors claim Novo Nordisk misled the market about CagriSema's tolerability, after disappointing clinical trial results wiped billions off its market cap.
The original article opens on the publisher's website.
More from Economy
View topic →China dissented from G20 statement opposing 'cheap exports' flooding market, Bessent says
cnbc
Sep 1, 2026 · 16:52
US diesel prices soar as Trump hauls in refiners
financialTimes
Sep 1, 2026 · 14:18
Anthropic's Claude Fable 5.1 and Mythos 5.1 arrive with a 75% cost reduction for Fable cache reads
ventureBeat
Sep 1, 2026 · 11:41
Prediction market traders think job creation rebounded in August
cnbc
Sep 1, 2026 · 11:16
Your files stay put: Perplexity’s hybrid AI keeps confidential data off the cloud
ventureBeat
Sep 1, 2026 · 08:00